BioSolution Designs & RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic Development

BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, today announced its ongoing strategic collaboration with RoosterBio, a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.

This partnership leverages BSD’s multigenic design and assembly platform, Bird of Prey, and cell engineering expertise along with RoosterBio’s cutting-edge MSC and exosome bioprocessing products, manufacturing protocols, and analytical services to simplify the development and manufacturing of engineered MSC derived therapies.

Together, BSD and RoosterBio deliver an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics, including BSD’s genetic engineering expertise and RoosterBio’s critical raw materials, expert process development, and advanced analytical characterization. Both teams have proven capabilities to deliver engineered therapies that possess a favorable global regulatory profile.

Dr. Thomas D. Reed, CEO of BSD, commented on the partnership, saying, “Mesenchymal stem cells represent a major untapped resource with broad therapeutic utility, from regenerative medicine to treating rare diseases. Understanding all too well that ‘The Product is the Process,’ we are thrilled to collaborate with RoosterBio, whose raison d’etre revolves around controlling all aspects of scalable cGMP manufacturing and characterization of human MSCs and MSC-derived exosomes. This partnership will not only benefit our internal therapeutic initiatives but will provide a seamless transition for BSD’s OspreyBio customers to send multigenic therapeutic candidates to RoosterBio for efficient manufacturing.”

“BSD is at the leading edge of advanced therapy engineering,” said Tim Kelly, CEO of RoosterBio. “By combining Biosolution Designs’ innovative multigenic technologies with our well-established cell therapy products and scalable bioprocess manufacturing platforms, we will accelerate the clinical progression of the next generation of cell and exosome therapeutics.”

SourceRoosterBio

Leave a Reply

Your email address will not be published. Required fields are marked *

*